StreetInsider.com News Articles

enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial

Fri, 02 Oct 2026 08:44:00 -0400

IRVINE, CA / ACCESS Newswire / October 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company will present its investigational enVVe^® System at The VEINS 2026 in Las Vegas, Nevada.

The presentation will take place on Sunday, October 4, 2026 at the Blue Sky Breakfast consisting of a gathering of specialists focused on advances in venous and vascular disease. The presentation will be followed by panel discussion and Q&A session.

Earlier this year, the Company received FDA Investigational Device Exemption (IDE) approval to initiate

enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial

Fri, 02 Oct 2026 08:44:00 -0400

Earlier this year, the Company received FDA Investigational Device Exemption (IDE) approval to initiate

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

Wed, 16 Sep 2026 08:50:00 -0400

New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spin

Real answers to what investors need to know about enVVeno and why they need to know it

Watch the inaugural episode here

IRVINE, CA / ACCESS Newswire / September 16, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced the launch of "WTF Rob Berman" a new video series that provides the information that investors need to know, in straight talk, with no corporate spin.

Hosted by enVVeno Medical

enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series

Wed, 16 Sep 2026 08:50:00 -0400

New CEO-led video series provides investors with straight talk, just the facts, with no B.S. or corporate spin

Real answers to what investors need to know about enVVeno and why they need to know it

Watch the inaugural episode here

Hosted by enVVeno Medical

Form SCHEDULE 13D/A enVVeno Medical Corp Filed by: Braeden Lichti

Tue, 15 Sep 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260915/27064759.html

Form 4 enVVeno Medical Corp For: Sep 11 Filed by: Duhay Francis

Mon, 14 Sep 2026 18:57:00 -0400

si-local-file:///var/storage/secattach/20260914/27059667.html

Form 144 enVVeno Medical Corp Filed by: Duhay Francis

Fri, 11 Sep 2026 10:20:00 -0400

si-local-file:///var/storage/secattach/20260911/27051510.html

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Access the video webcast here

IRVINE, CA / ACCESS Newswire / September 11, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.

The presentation, featuring Robert Berman, Chief Executive Officer of enVVeno Medical, provides an overview of the Company and its innovative enVVe® System, as well as recent corporate and clinical developments.

The on-demand presentation is available for viewing beginning today, September 11, 2026,

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Fri, 11 Sep 2026 07:00:00 -0400

Access the video webcast here

The on-demand presentation is available for viewing beginning today, September 11, 2026,

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video Webcast Now Available Here

IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference.

For the event, Mr. Berman highlighted the Company's investment opportunity, including the significant unmet need for effective treatment options for patients with severe Deep Venous Insufficiency (DVI) and the substantial market opportunity for Company's non-surgical replacement venous

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video Webcast Now Available Here

enVVeno Medical (NVNO) files $100M mixed shelf

Fri, 21 Aug 2026 16:36:26 -0400

enVVeno Medical (NASDAQ: NVNO) filed $100,000,000 mixed shelf of:

COMMON STOCK

PREFERRED STOCK

PURCHASE CONTRACTS

WARRANTS

SUBSCRIPTION RIGHTS

DEPOSITARY SHARES

DEBT SECURITIES

UNITS

enVVeno Medical (NVNO) files $100M mixed shelf

Fri, 21 Aug 2026 16:36:26 -0400

enVVeno Medical (NASDAQ: NVNO) filed $100,000,000 mixed shelf of:

COMMON STOCK

PREFERRED STOCK

PURCHASE CONTRACTS

WARRANTS

SUBSCRIPTION RIGHTS

DEPOSITARY SHARES

DEBT SECURITIES

UNITS

Form S-3 enVVeno Medical Corp

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961806.html

Form S-3 enVVeno Medical Corp

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961806.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932855.html

Form SCHEDULE 13G/A enVVeno Medical Corp Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932855.html

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatm

Tue, 04 Aug 2026 08:46:00 -0400

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve

Publication Highlights:

Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders
More than $32,000 projected healthcare savings per patient over five years
Approximately 2.2 fewer venous ulcers per patient compared to standard of care
Approximately $4,100 projected cost savings per each rVCSS* point of clinical improvement
Economically dominant versus compression therapy and

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatm

Tue, 04 Aug 2026 08:46:00 -0400

Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be used to support future coverage determinations and reimbursement policies for enVVeno Medical's enVVe non-surgical replacement venous valve
Publication Highlights:
Peer-reviewed publication in the Journal of Vascular Surgery: Venous and Lymphatic Disorders
More than $32,000 projected healthcare savings per patient over five years
Approximately 2.2 fewer venous ulcers per patient compared to standard of care
Approximately $4,100 projected cost savings per each rVCSS* point of clinical improvement
Economically dominant versus compression therapy and

enVVeno Medical (NVNO) Misses Q2 EPS by 537c

Fri, 31 Jul 2026 09:19:19 -0400

enVVeno Medical (NASDAQ: NVNO) reported Q2 EPS of ($5.37).
For earnings history and earnings-related data on enVVeno Medical (NVNO) click here.

enVVeno Medical posts Q2 2026 results, gets FDA nod for venous valve trial

Fri, 31 Jul 2026 08:31:51 -0400

enVVeno Medical Corporation (NASDAQ: NVNO) reported its second quarter 2026 financial results and disclosed that it received U.S. Food and Drug Administration Investigational Device Exemption (IDE) approval to begin a pivotal trial for its enVVe System, a minimally invasive replacement venous valve designed for patients with severe deep chronic venous insufficiency.
The company recorded a net loss of $3.6 million, or $5.37 per basic and diluted share, for the quarter ended June 30, 2026, compared to a net loss of $6.7 million, or $11.52 per basic and diluted share, for the same period in 2025.
As of June 30, 2026, enVVeno Medical

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Fri, 31 Jul 2026 08:30:00 -0400

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027

IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the second quarter ended June 30, 2026, and highlighted by the significant regulatory milestone of receiving U.S. Food and Drug Administration (FDA) IDE approval to begin the

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

Fri, 31 Jul 2026 08:30:00 -0400

Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027

IRVINE, CA / ACCESS Newswire / July 31, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today reported financial results for the second quarter ended June 30, 2026, and highlighted by the significant regulatory milestone of receiving U.S. Food and Drug Administration (FDA) IDE approval to begin the

Form 10-Q enVVeno Medical Corp For: Jun 30

Thu, 30 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260730/26843542.html

Form 10-Q enVVeno Medical Corp For: Jun 30

Thu, 30 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260730/26843542.html